Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
NCT02023359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7
Last updated 2015-12-29
Summary
An observational study in patients with advanced ER+, HER2 negative breast cancer, who are treated with everolimus and exemestane in combination. The objective of the study is to assess the safety pattern of everolimus in a real world setting.
Conditions
Interventions
- DRUG
-
Everolimus and exemestane
Sponsors & Collaborators
-
Novartis Healthcare A/S
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2015-04-30
- Completion
- 2015-04-30
Countries
- Denmark
Study Locations
More Related Trials
-
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
NCT02007512 ·Status: COMPLETED ·Phase: PHASE2
-
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
NCT02598557 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
NCT01743560 ·Status: COMPLETED ·Phase: PHASE4
-
Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women
NCT02028364 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
NCT01151046 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
NCT01831076 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616 ·Status: RECRUITING ·Phase: PHASE3
-
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
NCT02753686 ·Status: COMPLETED
-
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
NCT03219476 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
NCT00767520 ·Status: COMPLETED ·Phase: PHASE2
-
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
NCT01499160 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
NCT00553410 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
NCT00902954 ·Status: UNKNOWN ·Phase: PHASE3
-
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
NCT00107016 ·Status: COMPLETED ·Phase: PHASE2
-
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
NCT02820961 ·Status: COMPLETED ·Phase: PHASE1
-
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
NCT02228681 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
NCT00793546 ·Status: TERMINATED ·Phase: PHASE2
-
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
NCT02511639 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
NCT02520063 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
NCT00330317 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
NCT05730647 ·Status: ACTIVE_NOT_RECRUITING
-
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
NCT04666805 ·Status: UNKNOWN
-
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
NCT00248170 ·Status: COMPLETED ·Phase: PHASE3